Evidence map›Paper›PMID 36296168›Full record

ArticleMicroorganisms2022

Impact and Tolerance of Immunosuppressive Treatments in Patients Living with HIV with Inflammatory or Autoimmune Diseases.

Zélie Guitton, Nathalie Viget, Laure Surgers, Antoine Cheret, Clotilde Fontier, Laurène Deconinck, Pierre Bataille, Agnès Meybeck, Hélène Bazus, Olivier Robineau

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zélie GuittonInfectious Disease Department, Dr Schaffner Hospital, F-62300 Lens, France.
Nathalie VigetService Universitaire des Maladies Infectieuses, CH de Tourcoing, F-59210 Tourcoing, France.
Laure SurgersINSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GHU AP-HP, Sorbonne Univsersité, Service des Maladies Infectieuses et Tropicales, F-75012 Paris, France.
Antoine CheretAP-HP, Service de Médecine Interne et d'Immunologie Clinique, Hôpital Bicêtre, Le Kremlin-Bicêtre, plateforme de médecine ambulatoire CHU de Guadeloupe, UFR Médecine, Université des Antille, F-94270 Kremlin-Bicêtre, France.
Clotilde FontierInfectious Disease Department, Valenciennes Hospital, F-59300 Valenciennes, France.
Laurène DeconinckInfectious Disease Department, Raymond Poincarré Hospital, APHP, F-92380 Garches, France.
Pierre BatailleInfectious Disease Department, Boulogne sur Mer Hospital, F-62200 Boulogne sur Mer, France.
Agnès MeybeckService Universitaire des Maladies Infectieuses, CH de Tourcoing, F-59210 Tourcoing, France.
Hélène BazusInfectious Disease Department, Dr Schaffner Hospital, F-62300 Lens, France.
Olivier RobineauService Universitaire des Maladies Infectieuses, CH de Tourcoing, F-59210 Tourcoing, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients living with HIV (PLWHIV) can develop autoimmune diseases (AD) needing immunosuppressive treatments (IST). This study aims to describe the impact of IST in PLWHIV.

methodsThis was a multicentric retrospective observational study in six HIV referral centers on PLWHIV under IST for AD. Demographic factors, viral co-infections, immunovirological status before and under IST, infectious events, and their descriptions were collected and described focusing on infectious events, immunovirological variations, and IST effectiveness.

results9480 PLWHIV were screened for inclusion. Among them, 138 (1.5%) had a history of auto-immune disease, among which 32 (23%) received IST. There was mainly spondyloarthropathy (28%) and the most commonly used IST was methotrexate. The median follow-up under IST was 3.8 years (2.7; 5.9). There were 15 infectious events (0.5 events/individuals) concerning nine patients. At the last medical follow-up, 81% of these were in remission of their AD. Under IST, there was an increase in CD4 during follow-up (629 vs. 827 CD4/mm

conclusionsThis study supports a growing evidence base that IST can be used safely and effectively in PLWHIV with careful monitoring.

Indexed as

anti-TNFαauto-immune disorderHIVimmunosuppressive treatmentinflammatory diseasesmethotrexate

Identifiers

PMID36296168
PMCPMC9610421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.